Voya Investment Management LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 6.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 90,247 shares of the medical instruments supplier’s stock after buying an additional 5,591 shares during the period. Voya Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $16,154,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Public Sector Pension Investment Board increased its stake in shares of Becton, Dickinson and Company by 28.9% in the third quarter. Public Sector Pension Investment Board now owns 56,455 shares of the medical instruments supplier’s stock worth $10,606,000 after buying an additional 12,666 shares during the period. Global Retirement Partners LLC boosted its position in Becton, Dickinson and Company by 24.8% during the 3rd quarter. Global Retirement Partners LLC now owns 9,710 shares of the medical instruments supplier’s stock valued at $1,738,000 after buying an additional 1,927 shares during the period. Sompo Asset Management Co. Ltd. grew its holdings in Becton, Dickinson and Company by 4.9% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 15,780 shares of the medical instruments supplier’s stock worth $2,825,000 after acquiring an additional 733 shares during the last quarter. First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 0.5% in the 3rd quarter. First Eagle Investment Management LLC now owns 13,883,689 shares of the medical instruments supplier’s stock worth $2,485,180,000 after acquiring an additional 68,354 shares during the last quarter. Finally, Bridges Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 2.3% in the third quarter. Bridges Investment Management Inc. now owns 17,993 shares of the medical instruments supplier’s stock valued at $3,221,000 after acquiring an additional 400 shares during the period. Institutional investors own 86.97% of the company’s stock.
Analyst Ratings Changes
Several brokerages have recently commented on BDX. Wolfe Research began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating for the company. Zacks Research cut Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Citigroup lifted their price objective on Becton, Dickinson and Company from $208.00 to $241.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $197.47.
View Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Price Performance
Shares of BDX opened at $212.19 on Friday. The stock has a market cap of $58.47 billion, a PE ratio of 51.25, a price-to-earnings-growth ratio of 3.56 and a beta of 0.22. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. Becton, Dickinson and Company has a fifty-two week low of $140.11 and a fifty-two week high of $220.36. The firm’s 50-day simple moving average is $194.40 and its two-hundred day simple moving average is $170.85.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. The business had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.96 earnings per share. Analysts anticipate that Becton, Dickinson and Company will post 13.21 earnings per share for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be paid a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 101.45%.
Becton, Dickinson and Company declared that its board has authorized a share buyback program on Thursday, November 5th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy up to 3.6% of its shares through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its shares are undervalued.
Insider Activity
In other news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,310 shares of company stock worth $688,650 over the last three months. 0.40% of the stock is currently owned by insiders.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
